1. Home
  2. ENTA vs BWMX Comparison

ENTA vs BWMX Comparison

Compare ENTA & BWMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$15.87

Market Cap

486.3M

Sector

Health Care

ML Signal

HOLD

Logo Betterware de Mexico S.A.P.I. de C.V.

BWMX

Betterware de Mexico S.A.P.I. de C.V.

HOLD

Current Price

$14.19

Market Cap

495.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
BWMX
Founded
1995
1995
Country
United States
Mexico
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Catalog/Specialty Distribution
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
486.3M
495.6M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ENTA
BWMX
Price
$15.87
$14.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$20.40
$22.50
AVG Volume (30 Days)
370.9K
24.4K
Earning Date
02-09-2026
10-23-2025
Dividend Yield
N/A
10.53%
EPS Growth
N/A
15.49
EPS
N/A
1.49
Revenue
$65,324,000.00
$775,128,445.00
Revenue This Year
$0.99
$3.50
Revenue Next Year
$0.19
$5.30
P/E Ratio
N/A
$9.51
Revenue Growth
N/A
3.60
52 Week Low
$4.09
$7.00
52 Week High
$17.15
$15.00

Technical Indicators

Market Signals
Indicator
ENTA
BWMX
Relative Strength Index (RSI) 60.04 53.25
Support Level $14.07 $13.53
Resistance Level $17.15 $14.69
Average True Range (ATR) 0.95 0.34
MACD -0.01 -0.01
Stochastic Oscillator 56.71 57.04

Price Performance

Historical Comparison
ENTA
BWMX

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About BWMX Betterware de Mexico S.A.P.I. de C.V.

Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided in seven categories of the home organization: Kitchen and food preservation, Home solutions, Bedroom, Bathroom, Laundry & Cleaning, Tech & mobility and wellness. The JAFRA's segment is divided into four categories beauty and personal care: fragrance, color (cosmetics), skin care and toiletries. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.

Share on Social Networks: